Pembrolizumab Plus Olaparib for Patients With Previously Treated and Biomarker-Unselected Metastatic Castration-Resistant Prostate Cancer: The Randomized, Open-Label, Phase III KEYLYNK-010 Trial.
Nom du journal : J Clin Oncol
Année : 2023
Volume : 41
Page de départ : 3839-3850
